About: Everolimus in combination with octreotide long-acting repeatable in a first-line setting for patients with neuroendocrine tumors: an ITMO group study

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Everolimus in combination with octreotide long-acting repeatable in a first-line setting for patients with neuroendocrine tumors: an ITMO group study Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 18 April 2014

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована в серпні 2014 (uk) im August 2014 veröffentlichter wissenschaftlicher Artikel (de) scientific article published on 18 April 2014 (en) artículu científicu espublizáu n'abril de 2014 (ast) գիտական հոդված հրատարակված 2014 թվականի ապրիլի 18-ին (hy)
publication date	wds:Q57109641-C001AECF-0E8F-43DC-A9A4-CC58E98954AB
publication date	2014-04-18 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q57109641-0A387323-8968-462B-A148-F3CF6525CBF4
language of work or name	English
cites work	wds:Q57109641-1F6FC777-EEC2-43D6-B097-5BB1089D9F44 wds:Q57109641-45D8A604-5DB6-47FF-95C2-96F779A2246E wds:Q57109641-45FB5552-1238-4DC2-8A1F-BF9845403389 wds:Q57109641-4D3A35E2-67D3-438D-AB1A-30E38A9C9264 wds:Q57109641-4FB0E4D3-60F3-4F6B-969E-3EBDC25D7807 wds:Q57109641-565C7412-0D15-4EFD-9C2C-2E515145EA42 wds:Q57109641-621B3954-5FD0-463B-BF7A-70E0BA329B82 wds:Q57109641-6AC24C6D-7A5D-4639-9CA9-38B970A1CD1F wds:Q57109641-80D2CF2D-7A02-4A42-A7A0-4541CB844D16 wds:Q57109641-8369ACCC-B1B5-4915-BA47-C218D15E5CE7 wds:Q57109641-8619FA39-2687-49BB-84C0-6B33409254DE wds:Q57109641-87E2079F-B181-4C9F-9FF2-5CCA7A0D19D6 wds:Q57109641-8E08FEE5-8A2E-41D8-A7BB-B03F1F347F7E wds:Q57109641-958DF8E4-15E2-4250-9480-5A71E488894C wds:Q57109641-985F5D79-55D3-47B5-8479-7138F8F83ABE wds:Q57109641-9D9483B1-1C71-454A-84DA-65CA3706ED90 wds:Q57109641-A085C34B-8688-4E9C-8884-C38CC3BBF210 wds:Q57109641-A9AB67DF-AA66-4DFB-BBD2-013E31A48458 wds:Q57109641-B4DE87E4-CCDE-4A0E-8D42-1E19708C3732 wds:Q57109641-BF55F956-6899-43F2-9613-8EE42B6154B0 wds:Q57109641-D6823D72-E247-4133-AB43-1371D86BF94A wds:Q57109641-DDD07823-D6C7-40DF-B4D7-A9D1063F7C91 wds:Q57109641-EB961CF5-E719-4926-849C-54702D972760 wds:Q57109641-F3192B6C-E7D4-487E-903C-C1917EDA9952 wds:Q57109641-F3DECE07-3EFC-4A2B-8855-9AF29BDE828A wds:Q57109641-F78EC41E-925D-4EAB-A355-1C95272C2827
cites work	Everolimus in advanced pancreatic neuroendocrine tumors: the clinical experience Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study Innovations therapy: mammalian target of rapamycin (mTOR) inhibitors for the treatment of neuroendocrine tumors Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group Sunitinib malate for the treatment of pancreatic neuroendocrine tumors Everolimus for advanced pancreatic neuroendocrine tumors. Antiproliferative effect of somatostatin analogs in gastroenteropancreatic neuroendocrine tumors Everolimus plus octreotide long-acting repeatable in patients with colorectal neuroendocrine tumors: a subgroup analysis of the phase III RADIANT-2 study Somatostatin activation of mitogen-activated protein kinase via somatostatin receptor 1 (SSTR1) mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt Activity of sunitinib in patients with advanced neuroendocrine tumors One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States Pancreatic neuroendocrine tumors: the impact of surgical resection on survival Development of everolimus, a novel oral mTOR inhibitor, across a spectrum of diseases Antitumor activity of rapamycin and octreotide as single agents or in combination in neuroendocrine tumors Somatostatin/somatostatin receptor signalling: phosphotyrosine phosphatases. The NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the Jejunum, Ileum, Appendix, and Cecum 5-Fluorouracil, dacarbazine, and epirubicin in the treatment of patients with neuroendocrine tumors Everolimus for advanced pancreatic neuroendocrine tumours: a subgroup analysis evaluating Japanese patients in the RADIANT-3 trial mTOR activation in well differentiated pancreatic neuroendocrine tumors: a retrospective study on 34 cases Current understanding of the molecular biology of pancreatic neuroendocrine tumors Molecular pathogenesis of neuroendocrine tumors: implications for current and future therapeutic approaches Peptide receptor radionuclide therapy as a potential tool for neoadjuvant therapy in patients with inoperable neuroendocrine tumours (NETs)
author name string	wds:Q57109641-48E8009F-34F2-4640-8944-F9606659C9E0 wds:Q57109641-49C51664-CAD6-4ED2-8347-88C871DA8229 wds:Q57109641-4B4A3B4E-3F92-4351-81D2-7D3C3BB38F25 wds:Q57109641-5566F29E-B4F2-4865-BBE1-D7A20485C19D wds:Q57109641-74B918F0-DE53-46F7-BE1C-CFC579136493 wds:Q57109641-7C956745-C229-45F0-84D7-EE163ED4CF4A wds:Q57109641-CCBFF60A-C989-480A-AD6A-F8E0656153D7 wds:Q57109641-EF6774D9-604B-43AA-899C-8B1BA8EE5AC9 wds:Q57109641-F5F1F4A0-31C0-4546-BCD1-F629FCA63256 wds:Q57109641-FFE46CA9-E6ED-4545-BD95-ED415ACFC1E1
author name string	Francesca Spada Sergio Ricci Emilio Bajetta Monica Valente Francesca Pucci Laura Catena Giusi Blanco Pamela Biondani Nadia Bianco Chiara Maria Mauri
rdfs:label	Everolimus in combination with octreotide long-acting repeatable in a first-line setting for patients with neuroendocrine tumors: an ITMO group study (en) Everolimus in combination with octreotide long-acting repeatable in a first-line setting for patients with neuroendocrine tumors: an ITMO group study (nl)
skos:prefLabel	Everolimus in combination with octreotide long-acting repeatable in a first-line setting for patients with neuroendocrine tumors: an ITMO group study (en) Everolimus in combination with octreotide long-acting repeatable in a first-line setting for patients with neuroendocrine tumors: an ITMO group study (nl)
name	Everolimus in combination with octreotide long-acting repeatable in a first-line setting for patients with neuroendocrine tumors: an ITMO group study (en) Everolimus in combination with octreotide long-acting repeatable in a first-line setting for patients with neuroendocrine tumors: an ITMO group study (nl)
author	wds:Q57109641-9CDCF103-30EE-47A9-A023-763586E709D9 wds:Q57109641-AE23DE79-7049-4B3A-9E2B-A16E0A2A495D wds:Q57109641-B52CC43E-C247-45AC-8318-67BD88ACF808
author	Nicola Fazio Sara Pusceddu Michele Aieta
title	wds:Q57109641-654B0518-8220-4B4B-A577-6D19D2997618
title	Everolimus in combination with octreotide long-acting repeatable in a first-line setting for patients with neuroendocrine tumors: an ITMO group study (en)
page(s)	wds:Q57109641-A718ACE0-53CA-40A4-B274-8DEDB3F728AD
page(s)	2457-2463
instance of	wds:Q57109641-8B27543C-21A2-41DE-AFC9-089909EAF143

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 196 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software